These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

115 related items for PubMed ID: 2008157

  • 1. The acute effects of central- and peripheral-acting dopamine antagonists on plasma HVA in schizophrenic patients.
    Konicki PE, Owen RR, Litman RE, Pickar D.
    Life Sci; 1991; 48(14):1411-6. PubMed ID: 2008157
    [Abstract] [Full Text] [Related]

  • 2. Brain contribution to the haloperidol-induced increase in plasma homovanillic acid.
    Kendler KS, Heninger GR, Roth RH.
    Eur J Pharmacol; 1981 May 08; 71(2-3):321-6. PubMed ID: 7250191
    [Abstract] [Full Text] [Related]

  • 3. Plasma homovanillic acid as an index of central dopaminergic activity: studies in schizophrenic patients.
    Pickar D, Breier A, Kelsoe J.
    Ann N Y Acad Sci; 1988 May 08; 537():339-46. PubMed ID: 2904783
    [Abstract] [Full Text] [Related]

  • 4. Effects of debrisoquin on CSF and plasma HVA concentrations in man.
    Maas JW, Contreras SA, Bowden CL, Weintraub SE.
    Life Sci; 1985 Jun 03; 36(22):2163-70. PubMed ID: 3999921
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Plasma homovanillic acid as an index of brain dopamine metabolism: enhancement with debrisoquin.
    Sternberg DE, Heninger GR, Roth RH.
    Life Sci; 1983 May 23; 32(21):2447-52. PubMed ID: 6855448
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Assessment of the central dopaminergic index of plasma HVA in schizophrenia.
    Amin F, Davidson M, Kahn RS, Schmeidler J, Stern R, Knott PJ, Apter S.
    Schizophr Bull; 1995 May 23; 21(1):53-66. PubMed ID: 7770741
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Assessment of brain dopamine metabolism from plasma HVA and MHPG during debrisoquin treatment: validation in monkeys treated with MPTP.
    Kopin IJ, Bankiewicz KS, Harvey-White J.
    Neuropsychopharmacology; 1988 May 23; 1(2):119-25. PubMed ID: 3266957
    [Abstract] [Full Text] [Related]

  • 14. Neuroleptics, dopamine, and schizophrenia.
    Pickar D.
    Psychiatr Clin North Am; 1986 Mar 23; 9(1):35-48. PubMed ID: 2870480
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Perspectives on a time-dependent model of neuroleptic action.
    Pickar D.
    Schizophr Bull; 1988 Mar 23; 14(2):255-68. PubMed ID: 2904694
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Plasma HVA, neuroleptics, and dopaminergic plasticity.
    Dávila R.
    Biol Psychiatry; 1989 Jan 23; 25(1):1-3. PubMed ID: 2563229
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.